Patanjali Ayurved submits report on its Covid-19 drug to Ayush ministry

"Baba Ramdev has produced a new medicine. Whatever research they have done, it should come to the Ayush Ministry for authentication," Naik said

Patanjali
The Ayush minister said that the ministry would look into the report and then decide about giving final permission to the company over the medicine.
Press Trust of India Panaji
2 min read Last Updated : Jun 24 2020 | 7:30 PM IST
Union minister Shripad Naik on Wednesday said that Patanjali Ayurved has submitted to the Ayush ministry its report on the company's medicine, which it has launched with the claim that it can cure coronavirus in seven days.

The Ayush minister said that the ministry would look into the report and then decide about giving final permission to the company over the medicine.

He was speaking to PTI over the phone from New Delhi, a day after his ministry asked Patanjali Ayurved to provide "at the earliest" the composition and other details of the medicine. The ministry had also ordered the firm to stop advertising the product until the "issue" is examined.


"Baba Ramdev has produced a new medicine. Whatever research they have done, it should come to the Ayush Ministry for authentication," he said.

"We will be able to speak about it only when we look into the claims. I was told that they (Patanjali) have submitted a report to the ministry. The ministry will look into the report and final permission will be given after going through it," Naik said.

Patanjali Ayurved launched the 'Coronil and Swasari' medicine on Tuesday with the claim that it has discovered a cure for Covid-19. The firm claimed its medicine has shown 100 per cent favourable results during clinical trials on Covid-19 patients, except those on life support systems.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusPatanjali AyurvedAyush Ministry

Next Story